Filter News

Exicure, Inc. to Present at Jefferies 2018 Healthcare Conference on June 8th at 2:30 p.m. EDT

Published: Jun 04, 2018

SKOKIE, Ill.--(BUSINESS WIRE)-- Exicure, Inc., (OTCQB:XCUR), the pioneer in the development and application of three-dimensional Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, announced today that Dr. David Giljohann, Chief Executive Officer of Exicure, will present at the Jefferies 2018 Healthcare Conference on Friday, June 8, 2018 at 2:30 p.m. EDT in New York City at the Grand Hyatt New York.

A live webcast of the presentation will be available on the Events & Presentations section of Exicure's website, where it will also be archived and available for replay following the presentation for 30 days.

About Exicure, Inc.

Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Exicure is based outside of Chicago, IL. For more information, please visit www.exicuretx.com.

 

 

Contacts

Media:
MacDougall Biomedical Communications
Karen Sharma, 781-235-3060
ksharma@macbiocom.com
or
Investor:
The Del Mar Consulting Group, Inc.
Robert B. Prag, President, 858-794-9500
bprag@delmarconsulting.com

 
 

Source: Exicure, Inc.

Back to news